ArticleNature2023
Non-viral precision T cell receptor replacement for personalized cell therapy.
Open access · hybridAbstract readClinical Trial, Phase I
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers.
0numbers the graph read from it
0cells of the map it votes in
182citing papers in PubMed
25.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
182 citing papers in PubMed, 256 citations in OpenAlex.
- Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results.Nature medicine · 2024Trial
- Production and Purification of Cas9 Protein for Ribonucleoprotein Complex Formation.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Tregs transduced with a Ro60-reactive TCR have increased immunosuppressive functions in Sjögren's disease.iScience · 2026Article
- Computational design of optimized and preferentially paired human TCR constant regions for improved T cell function.Science advances · 2026Article
- Beyond Precision: A Multidimensional Framework for Selecting Genetic Medicine Platforms.Cells · 2026Review
- Simultaneous gene engineering of T cells with multiple neoantigen-specific T cell receptors for adoptive cell transfer.Molecular therapy. Advances · 2026Article
- The development of single-cell lineage tracing technology and its application in immunotherapy.Molecular therapy. Advances · 2026Review
- Adoptive cell therapy in lung cancer: progress, challenges, and prospects.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Strategies and mechanisms of precision genome engineering: From gene editing to genome writing.iMetaOmics · 2026Review
- Review
- Uncovering ectopic GC-like niches for tumor reactive lymphocyte priming in lung adenocarcinoma using Stereo-XCR-seq.Nature communications · 2026Article
- A modular γδ TCR-T platform combining KRAS pMHC targeting with re-dosable mRNA engager redirection.Journal of hematology & oncology · 2026Article
- A programmable DNA tetrahedron platform for selective and efficient capture of cells and proteins.Nature protocols · 2026Review
- A platform for parallel TCR cloning and testing enables anti-neoantigen tumor immunotherapy.JCI insight · 2026Article
- Breathing new life into T-cell receptor-engineered T-cell therapy in solid tumors: enhancing strategies to expand the universality of precision therapy.Experimental hematology & oncology · 2026Review
- Class I HDAC inhibition enhances the stem-like memory properties of CRISPR-engineered CAR T cells in neuroblastoma.Molecular therapy. Oncology · 2026Article
- Review
- Deciphering small sequence differences in T cell receptor-antigen pairing.Nature communications · 2026Article
- General prediction of T cell receptor antigen specificity from sequence using AlphaFold 3.bioRxiv : the preprint server for biology · 2026Article
- Hallmarks and correlates of effective adoptive cell immunotherapy for cancer.Nature reviews. Immunology · 2026Review
122 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
54 authors at 12 institutions in 1 country.
Susan P Foy *PACT Pharma, South San Francisco, CA, USA. sfoy@pactpharma.com.
Kyle Jacoby *PACT Pharma, South San Francisco, CA, USA.
Daniela A Bota *Department of Neurology and Chao Family Comprehensive Cancer Center, University of California, Irvine, CA, USA.
Theresa HunterPACT Pharma, South San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-6494-1294
Zheng PanPACT Pharma, South San Francisco, CA, USA.
Eric StawiskiPACT Pharma, South San Francisco, CA, USA.
Yan MaPACT Pharma, South San Francisco, CA, USA.
William LuPACT Pharma, South San Francisco, CA, USA.
Songming PengPACT Pharma, South San Francisco, CA, USA.
Clifford L WangPACT Pharma, South San Francisco, CA, USA.
Benjamin YuenPACT Pharma, South San Francisco, CA, USA.
Olivier DalmasPACT Pharma, South San Francisco, CA, USA.
Katharine HeeringaPACT Pharma, South San Francisco, CA, USA.
Barbara SenninoPACT Pharma, South San Francisco, CA, USA.
Andy ConroyPACT Pharma, South San Francisco, CA, USA.
Michael T BethunePACT Pharma, South San Francisco, CA, USA.
Ines MendePACT Pharma, South San Francisco, CA, USA.
William WhitePACT Pharma, South San Francisco, CA, USA.
Monica KukrejaPACT Pharma, South San Francisco, CA, USA.
Swetha GunturuPACT Pharma, South San Francisco, CA, USA.
Emily HumphreyPACT Pharma, South San Francisco, CA, USA.
Adeel HussainiPACT Pharma, South San Francisco, CA, USA.
Duo AnPACT Pharma, South San Francisco, CA, USA.
Adam J LittermanPACT Pharma, South San Francisco, CA, USA.
Boi Bryant QuachPACT Pharma, South San Francisco, CA, USA.
Alphonsus H C NgInstitute for Systems Biology, Seattle, WA, USA.
Yue LuInstitute for Systems Biology, Seattle, WA, USA.
Chad SmithPACT Pharma, South San Francisco, CA, USA.
Katie M CampbellDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-6491-4432
Daniel AnayaPACT Pharma, South San Francisco, CA, USA.
Lindsey SkrdlantPACT Pharma, South San Francisco, CA, USA.
Eva Yi-Hsuan HuangPACT Pharma, South San Francisco, CA, USA.
Ventura MendozaPACT Pharma, South San Francisco, CA, USA.
Jyoti MathurPACT Pharma, South San Francisco, CA, USA.
Luke DenglerPACT Pharma, South San Francisco, CA, USA.
Bhamini PurandarePACT Pharma, South San Francisco, CA, USA.
Robert MootPACT Pharma, South San Francisco, CA, USA.
Michael C YiPACT Pharma, South San Francisco, CA, USA.
Roel FunkePACT Pharma, South San Francisco, CA, USA.
Alison SibleyPACT Pharma, South San Francisco, CA, USA.
Todd Stallings-SchmittPACT Pharma, South San Francisco, CA, USA.
David Y OhDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USA.
Bartosz ChmielowskiDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-2374-3320
Mehrdad AbediDivision of Hematology/Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.ORCID http://orcid.org/0000-0003-4640-0977
Yuan YuanDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Jeffrey A SosmanDepartment of Medicine and Robert H. Lurie Cancer Center, Northwestern University, Evanston, IL, USA.
Sylvia M LeeClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-7425-2230
Adam J SchoenfeldThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
David BaltimoreDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.ORCID http://orcid.org/0000-0001-8723-8190
James R HeathInstitute for Systems Biology, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-5356-4385
Alex FranzusoffPACT Pharma, South San Francisco, CA, USA.
Antoni RibasDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles (UCLA), Los Angeles, CA, USA. ARibas@mednet.ucla.edu.ORCID http://orcid.org/0000-0003-3669-8458
Arati V RaoPACT Pharma, South San Francisco, CA, USA.
Stefanie J MandlPACT Pharma, South San Francisco, CA, USA. smandl@pactpharma.com.
Institute for Systems Biology · USUniversity of California, Los Angeles · USCalifornia Institute of Technology · USCity Of Hope National Medical Center · USFred Hutch Cancer Center · USMemorial Sloan Kettering Cancer Center · USNorthwestern University · USSan Francisco County Transportation Authority · USUC Davis Comprehensive Cancer CenterUniversity of California, Irvine · USUniversity of California, San Francisco · USVifor Pharma (United States) · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MWomen's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5MProject 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GRAEBER, THOMAS G · 2020 to 2024
$12.8MNext Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4MUCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3MIdentification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse eventsK08AI139375 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OH, DAVID YOONSUK · 2019 to 2023
$995kNCI NIH HHS P01 CA244118NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016042NCI NIH HHS R35 CA197633NCI NIH HHS T32 CA009120NIAID NIH HHS K08 AI139375
Abstract
T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells
Indexed as
Cell- and Tissue-Based TherapyGene EditingNeoplasmsPrecision MedicineReceptors, Antigen, T-CellT-LymphocytesTransgenesAntigens, NeoplasmBiopsyCRISPR-Cas SystemsCytokine Release SyndromeDisease ProgressionEncephalitisGene Knock-In TechniquesGene Knockout TechniquesGenes, T-Cell Receptor alphaAntigens, NeoplasmHLA AntigensReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.